A Study of LY3819253 (LY-CoV555) in Healthy Participants

Phase 1 Completed 25 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.

Timeline

Start: 2020-09-02
Primary completion: 2020-12-28
Completion: 2020-12-28

Publications

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bamlanivimab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Bamlanivimab	Monoclonal antibody	350 mg	Subcutaneous
Subject	Bamlanivimab	Monoclonal antibody	700 mg	Subcutaneous

Indications

No indication recorded.